Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Hypomagnesemia because of nedaplatin for cervical cancer: A case report

Hypomagnesemia because of nedaplatin for cervical cancer: A case report A 76‐year‐old woman with cervical cancer was treated with nedaplatin, a platinum‐based drug. After the initiation of the treatment, she became aware of numbness, dizziness, and loss of appetite. Exploration of the causes revealed no clues, but blood tests revealed hypocalcemia and hypomagnesemia. She was treated with intravenous calcium and magnesium, which resolved calcium, magnesium levels, and her symptoms. She was diagnosed with hypomagnesemia because of nedaplatin. Regular follow‐up is necessary for patients during or after nedaplatin. Awareness of electrolyte disturbances may elucidate the accurate diagnosis even in patients with obscure symptoms, particular in undergoing or following anticancer therapies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of General and Family Medicine Wiley

Hypomagnesemia because of nedaplatin for cervical cancer: A case report

Download PDF
4 pages

Loading next page...
 
/lp/wiley/hypomagnesemia-because-of-nedaplatin-for-cervical-cancer-a-case-report-NJx7N2bGKQ
Publisher
Wiley
Copyright
© 2023 Japan Primary Care Association
eISSN
2189-7948
DOI
10.1002/jgf2.630
Publisher site
See Article on Publisher Site

Abstract

A 76‐year‐old woman with cervical cancer was treated with nedaplatin, a platinum‐based drug. After the initiation of the treatment, she became aware of numbness, dizziness, and loss of appetite. Exploration of the causes revealed no clues, but blood tests revealed hypocalcemia and hypomagnesemia. She was treated with intravenous calcium and magnesium, which resolved calcium, magnesium levels, and her symptoms. She was diagnosed with hypomagnesemia because of nedaplatin. Regular follow‐up is necessary for patients during or after nedaplatin. Awareness of electrolyte disturbances may elucidate the accurate diagnosis even in patients with obscure symptoms, particular in undergoing or following anticancer therapies.

Journal

Journal of General and Family Medicine – Wiley

Published: Jul 1, 2023

Keywords: hypomagnesemia; nedaplatin; uterine cervical neoplasms

References

  • Cisplatin and hypomagnesemia
    Lajer, H; Daugaard, G
  • The second‐generation anticancer drug nedaplatin: a theoretical investigation on the hydrolysis mechanism
    Alberto, ME; Lucas, MF; Pavelka, M
  • Concurrent chemoradiotherapy with nedaplatin in patients with stage IIA to IVA cervical carcinoma
    Fujioka, T; Yasuoka, T; Koizumi, M
  • Clinical efficacy of nedaplatin‐based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku gynecologic cancer unit study
    Kagabu, M; Shoji, T; Murakami, K; Omi, H; Honda, T; Miura, F
  • Guidelines for treatment of uterine cervical cancer (2022 edition)
    Nagase, S; Kobayashi, Y; Baba, T
  • Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1‐3 and multidrug and toxin extrusion family)
    Yonezawa, A; Masuda, S; Yokoo, S; Katsura, T; Inui, KI
  • Electrolyte disorders with platinum‐based chemotherapy: mechanisms, manifestations and management
    Oronsky, B; Caroen, S; Oronsky, A; Dobalian, VE; Oronsky, N; Lybeck, M
  • Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin
    Schilsky, RL; Anderson, T
  • Results of NCI‐sponsored phase I trials with carboplatin
    Foster, BJ; Clagett‐Carr, K; Leyland‐Jones, B; Hoth, D